Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: Possible implications for the cognitive enhancing properties of EGb 761®

International Psychogeriatrics

Volumn 24, Issue SUPPL. 1, 2012, Pages

  Kehr, J ^a   Yoshitake, S ^a   Ijiri, S ^b   Koch, E ^c   Noldner M ^c   Yoshitake, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Ginkgo biloba; microdialysis; neurotransmitter release; rat

Indexed keywords

3 O [2'' O [6''' O (P HYDROXY TRANS CINNAMOYL) BETA DEXTRO GLUCOSYL] ALPHA L RHAMNOSYL]KAEMPFEROL; 3 O [2'' O [6''' O (P HYDROXY TRANS CINNAMOYL) BETA DEXTRO GLUCOSYL] ALPHA L RHAMNOSYL]QUERCETIN; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; DOPAMINE; FLAVANOL DERIVATIVE; GINKGO BILOBA EXTRACT; HOMOVANILLIC ACID; ISORHAMNETIN; NORADRENALIN; SEROTONIN; UNCLASSIFIED DRUG;

ACETYLCHOLINE BRAIN LEVEL; ACYLATION; ADRENERGIC TRANSMISSION; ARTICLE; CHOLINERGIC TRANSMISSION; COGNITION; DRUG EFFECT; IN VIVO STUDY; MICRODIALYSIS; MIDDLE FRONTAL GYRUS; NONHUMAN; NORADRENALIN BRAIN LEVEL; PLANT LEAF; PREFRONTAL CORTEX;

3,4-DIHYDROXYPHENYLACETIC ACID; ACETYLCHOLINE; ANIMALS; COGNITION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; NOREPINEPHRINE; PLANT EXTRACTS; PREFRONTAL CORTEX; RATS; SEROTONIN;

EID: 84863925130     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610212000567     Document Type: Article

References (58)

1. Abdel-Kader, R. et al. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research 56, 493-502.
2. Ahlemeyer, B. and Krieglstein, J. (2003). Neuroprotective effects of Ginkgo biloba extract. Cellular and Molecular Life Sciences, 60, 1779-1792.
3. Ahmad, M. et al. (2005). Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. Journal of Neurochemistry, 93, 94-104.
4. Andrieu, S. et al. (2003). EPIDOS study. Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 58, 372-377.
5. Andrieu, S. and GuidAge study GROUP. (2008). GuidAge study: a 5-year double blind, randomised trial of EGb 761® for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Current Alzheimer Research, 5, 406-415.
6. Bachinskaya, N., Hoerr, R. and Ihl, R. (2011). Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®: findings from a randomized controlled trial. Neuropsychiatric Disease and Treatment, 7, 209-215.
7. Bartus, R. T., Dean, R. L. III, Beer, B. and Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408-414.
8. Bedir, E. et al. (2002). Biologically active secondary metabolites from Ginkgo biloba. Journa of Agricultural and Food Chemistry, 50, 3150-3155.
9. Blecharz-Klin, K., Piechal, A., Joniec, I., Pyrzanowska, J. and Widy-Tyszkiewicz, E. (2009). Pharmacological and biochemical effects of Ginkgo biloba extract on learning, memory consolidation and motor activity in old rats. Acta Neurobiologiae Experimentalis (Warsaw), 69, 217-231.
10. Brunello, N., Racagni, G., Clostre, F., Drieu, K. and Braquet, P. (1985). Effects of an extract of Ginkgo biloba on noradrenergic systems of rat cerebral cortex. Pharmacological Research Communications, 17, 1063-1072.
11. Castner, S. A. and Goldman-Rakic, P. S. (2004). Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. Journal of Neuroscience, 24, 1446-1450.
12. Chan, P. C, Xia, Q. and Fu, P. P. (2007). Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. Journal of Environmental Science and Health, Part C: Environmental Carcinogensis and Ecotoxicology Reviews, 25, 211-244.
13. Coyle, J. T., Price, D. L. and DeLong, M. R. (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science, 219, 1184-1190.
14. Dartigues, JF, Carcaillon, L, Helmer, C, Lechevallier, N, Lafuma, A, Khoshnood, B (2007). Vasodilators and Nootropics as Predictors of Dementia and Mortality in the PAQUID Cohort. J Am Geriatr Soc 55: 395-399.
15. DeFeudis, F. V. (2003). A brief history of EGb 761® and its therapeutic uses. Pharmacopsychiatry, 36 (Suppl 1), S2-7.
16. DeFeudis, F. V. and Drieu, K. (2000). Ginkgo biloba extract (EGb 761®) and CNS functions: basic studies and clinical applications. Current Drug Targets, 1, 25-58.
17. DeKosky, S. T. et al. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300, 2253-2262.
18. Dodge, H. H., Zitzelberger, T., Oken, B. S., Howieson, D. and Kaye, J. (2008). A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology, 70, 1809-1817.
19. Fehske, C. J., Leuner, K. and Müller, W. E. (2009). Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacological Research, 60, 68-73.
20. Grass-Kapanke, B., Busmane, A., Lasmanis, A., Hoerr, A. and Kaschel, R. (2011). Effects of Ginkgo biloba special extract EGb 761® in very mild cognitive impairment (vMCI). Neuroscience & Medicine, 2, 48-56.
21. Goldman-Rakic, P. S. (1995). Cellular basis of working memory. Neuron, 14, 477-485.
22. Goldman-Rakic, P. S., Muly, E. C. III and Williams, G. V. (2000). D(1) receptors in prefrontal cells and circuits. Brain Research. Brain Research Reviews, 31, 295-301.
23. Hasler, A. (1993). Ginkgo, ein modernes Phytopharmakon? Schweizerische Apotheker Zeitung, 131, 315-316.
24. Hasler, A. (2000). Chemical constituents of Ginkgo biloba. In T. A. van Beek (ed.), Ginkgo biloba (pp. 109-142). The Netherlands: Harwood Academic.
25. Hertel, P., Nomikos, G. G. and Svensson, T. H. (1999). Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. European Journal of Pharmacology, 371, 153-158.
26. Huguet, F. andTarrade, T. (1992). Alpha 2-adrenoceptor changes during cerebral ageing. The effect of Ginkgo biloba extract. Journal of Pharmacy and Pharmacology, 44, 24-27.
27. Huguet, F., Drieu, K. and Piriou, A. (1994). Decreased cerebral 5-HT1A receptors during ageing: reversal by Ginkgo biloba extract (EGb 761®). Journal of Pharmacy and Pharmacology, 46, 316-318.
28. Ihl, R. et al. (2011). Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized controlled trial. International Journal of Geriatric Psychiatry, 26, 1186-1194
29. IQWiG Institute for Quality and Efficacy in Health Care (2008). Ginkgo in Alzheimer's disease. Executive Summary. Commission No. A05-19B. Available at: https://www. iqwig.de/download/A05-19B-Abschlussbericht- Ginkgohaltige- Praeparate-bei-Alzheimer-Demenz.pdf (last accessed 27 Sept. 2011)
30. Jerant, A., Chapman, B., Duberstein, P., Robbins, J. and Franks, P. (2011). Personality and medication non-adherence among older adults enrolled in a six-year trial. British Journal of Health Psychology, 16, 151-169.
31. Kaschel, R. (2011). Specific memory effects of Ginkgo biloba extract EGb 761® in middle-aged healthy volunteers. Phytomedicine, 18, 1202-1207.
32. Kim, D. H., Maneen, M. J. and Stahl, S. M. (2009). Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics, 6, 78-85.
33. Meltzer, H. Y. and Huang, M. (2008). In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Progress in Brain Research, 172, 177-197.
34. Müller, W. E. and Chatterjee, S. S. (2003). Cognitive and other behavioral effects of EGb 761® in animal models. Pharmacopsychiatry, 36 (Suppl. 1), S24-S31.
35. O'Brien, J. T. and Burns, A. on behalf of the BAP Dementia Consensus Group (2011). Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology, 25, 997-1019.
36. Pardon, M. C, Joubert, C, Perez-Diaz, F., Christen, Y., Launay, J. M. and Cohen-Salmon, C. (2000). In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761®). Mechanisms of Ageing and Development, 113, 157-168.
37. Paspalas, C. D. and Goldman-Rakic, P. S. (2005). Presynaptic D1 dopamine receptors in primate prefrontal cortex: target-specific expression in the glutamatergic synapse. Journal of Neuroscience, 25, 1260-1267.
38. Rojas, P., Serrano-García, N., Mares-Sámano, J. J., Medina-Campos, O. N., Pedraza-Chaverri, J. and Ögren, S. O. (2008). EGb 761® protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. European Journal of Neuroscience, 28, 41-50.
39. Satvat, E. and Mallet, P. E. (2009). Chronic administration of a Ginkgo biloba leaf extract facilitates acquisition but not performance of a working memory task. Psychopharmacology (Berlin), 202, 173-185.
40. Shah, Z. A., Sharma, P. and Vohora, S. B. (2003). Ginkgo biloba normalises stress-elevated alterations in brain catecholamines, serotonin and plasma corticosterone levels. European Neuropsychopharmacology, 13, 321-325.
41. Shin, J. C, Chen, K., Ridd, M. J. and Seif, I. (2000). Ginkgo biloba abolishes aggression in mice lacking MAO A. Antioxidants & Redox Signaling, 2, 467-471.
42. Singh, V., Singh, S. P. and Chan, K. (2010). Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. International Journal of Neuropsychopharmacology, 13, 257-271.
43. Stackman, R. W., Eckenstein, F., Frei, B., Kulhanek, D., Nowlin, J, and Quinn, J. F. (2003). Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Experimental Neurology, 184, 510-520.
44. Taylor, J. E. (1986). Neuromediator binding to receptors in the rat brain. The effect of chronic administration of Ginkgo biloba extract. (French). La Presse Médicale, 15, 1491-1493.
45. Tellez, S., Colpaert, F. andMarien, M. (1999). Alpha2-adrenoceptor modulation of cortical acetylcholine release in vivo. Neuroscience, 89, 1041-1050.
46. Terry, A. V. Jr. (2008). Role of the central cholinergic system in the therapeutics of schizophrenia. Current Neuropharmacology, 6, 286-292.
47. Terry, A. V. Jr. and Buccafusco, J. J. (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. Journal of Pharmacology and Experimental Therapeutics, 306, 821-827.
48. Thomas, D. N., Nutt, D. J. and Holman, R. B. (1998). Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. Journal of Psychopharmacology, 12, 366-370.
49. Vellas, B. and Guidage Study Group. (2010). Results of GuidAge: a 5-year placebo-controlled study of the efficacy of EGb 761(R) 120mg to prevent or delay Alzheimer's dementia onset in elderly subjects with memory complaint. Journal of Nutrition Health and Aging, 14 (Suppl. 2), S23-S23.
50. Viskupicova, J., Ondrejovic, M. and Sturdik, E. (2009). The potential and practical applications of acylated flavonoids. Pharmazie, 64, 355-360.
51. Wang, Y., Wang, L., Wu, J. and Cai, J. (2006). The in vivo synaptic plasticity mechanism of EGb 761®-induced enhancement of spatial learning and memory in aged rats. British Journal of Pharmacology, 148, 147-153.
52. Wang, B. S. et al. (2010). Effectiveness of sstandardized Ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: a bivariate random effect meta-analysis. Pharmacopsychiatry, 43, 86-91.
53. Weikop, P., Kehr, J. and Scheel-Krüger, J. (2004). The role of alpha1-and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. Journal of Psychopharmacology, 18, 395-403.
54. Weinmann, S., Roll, S., Schwarzbach, C., Vauth, C. and Willich, S. N. (2010). Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatrics, 10, 14. http://www.biomedcentral. com/1471-2318/10/14.
55. White, H. L., Scates, P. W. and Cooper, B. R. (1996). Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sciences, 58, 1315-1321.
56. Yoshitake, T., Kehr, J., Yoshitake, S., Fujino, K., Nohta, H. and Yamaguchi, M. (2004). Determination of serotonin, noradrenaline, dopamine and their metabolites in rat brain extracts and microdialysis samples by column liquid chromatography with fluorescence detection following derivatization with benzylamine and 1,2-diphenylethylenediamine.Journal of Chromatography: B, Analytical Technologies in the Biomedical and Life Sciences, 807, 177-183.
57. Yoshitake, T., Yoshitake, S. and Kehr, J. (2010). The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. British Journal of Pharmacology, 159, 659-668.
58. Zhang, W. F., Tan, Y. L., Zhang, X. Y., Chan, R. C., Wu, H. R. and Zhou, D. F. (2011). Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 72, 615-621.